Escape of HIV-1 from a CCR5 antagonist can reduce envelope-mediated entry

被引：0
|
作者：
Huang, W. [1 ]
Wojcik, L. [2 ]
Toma, J. [1 ]
Fransen, S. [1 ]
Stawiski, E. [1 ]
Whitcomb, J. [1 ]
Parkin, N. [1 ]
Strizki, J. [2 ]
Petropoulos, C. [1 ]
机构：
[1] Monogram Biosci, San Francisco, CA USA
[2] Schering Plough Res Inst, Kenilworth, NJ 07033 USA
来源：
ANTIVIRAL THERAPY | 2008年 / 13卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：A65 / A65
页数：1
相关论文
共 50 条
  • [41] CCR5 as target for HIV-1 gene therapy
    Nazari, Reza
    Joshi, Sadhna
    CURRENT GENE THERAPY, 2008, 8 (04) : 264 - 272
  • [42] Transmitted/Founder and Chronic HIV-1 Envelope Proteins Are Distinguished by Differential Utilization of CCR5
    Parker, Zahra F.
    Iyer, Shilpa S.
    Wilen, Craig B.
    Parrish, Nicholas F.
    Chikere, Kelechi C.
    Lee, Fang-Hua
    Didigu, Chuka A.
    Berro, Reem
    Klasse, Per Johan
    Lee, Benhur
    Moore, John P.
    Shaw, George M.
    Hahn, Beatrice H.
    Doms, Robert W.
    JOURNAL OF VIROLOGY, 2013, 87 (05) : 2401 - 2411
  • [43] Targeting Spare CC Chemokine Receptor 5 (CCR5) as a Principle to Inhibit HIV-1 Entry
    Jin, Jun
    Colin, Philippe
    Staropoli, Isabelle
    Lima-Fernandes, Evelyne
    Ferret, Cecile
    Demir, Arzu
    Rogee, Sophie
    Hartley, Oliver
    Randriamampita, Clotilde
    Scott, Mark G. H.
    Marullo, Stefano
    Sauvonnet, Nathalie
    Arenzana-Seisdedos, Fernando
    Lagane, Bernard
    Brelot, Anne
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (27) : 19042 - 19052
  • [44] Quantitative Deep Sequencing Reveals Dynamic HIV-1 Escape and Large Population Shifts during CCR5 Antagonist Therapy In Vivo
    Tsibris, Athe M. N.
    Korber, Bette
    Arnaout, Ramy
    Russ, Carsten
    Lo, Chien-Chi
    Leitner, Thomas
    Gaschen, Brian
    Theiler, James
    Paredes, Roger
    Su, Zhaohui
    Hughes, Michael D.
    Gulick, Roy M.
    Greaves, Wayne
    Coakley, Eoin
    Flexner, Charles
    Nusbaum, Chad
    Kuritzkes, Daniel R.
    PLOS ONE, 2009, 4 (05):
  • [45] CCR5Δ32 Genotypes in a German HIV-1 Seroconverter Cohort and Report of HIV-1 Infection in a CCR5Δ32 Homozygous Individual
    Oh, Djin-Ye
    Jessen, Heiko
    Kuecherer, Claudia
    Neumann, Konrad
    Oh, Nari
    Poggensee, Gabriele
    Bartmeyer, Barbara
    Jessen, Arne
    Pruss, Axel
    Schumann, Ralf R.
    Hamouda, Osamah
    PLOS ONE, 2008, 3 (07):
  • [46] Recent Progress in Small Molecule CCR5 Antagonists as Potential HIV-1 Entry Inhibitors
    Chen, Wenwen
    Zhan, Peng
    De Clercq, Erik
    Liu, Xinyong
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (01) : 100 - 112
  • [47] Structural model of CCR5 for the discovery of entry inhibitors for the therapeutic intervention of HIV-1 infection
    Das, Debananda
    Maeda, Kenji
    Tsuchiya, Kiyoto
    Mitsuya, Hiroaki
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 231
  • [48] In vivo emergence of HIV-1 resistance to the CCR5 antagonist vicriviroc:: findings from ACTG A5211
    Tsibris, A. M. N.
    Gulick, R. M.
    Su, Z.
    Hughes, M. D.
    Flexner, C.
    Wilkin, T.
    Gross, R.
    Hirsch, M.
    Skolnick, P. R.
    Coakley, E.
    Greaves, W. L.
    Kuritzkes, D. R.
    ANTIVIRAL THERAPY, 2007, 12 (05) : S15 - S15
  • [49] Investigating HIV-1 Resistance to CCR5 Antagonist Maraviroc for the Design of New Prevention Strategies
    Flynn, Jacqueline K.
    Roche, Michael
    Paukovics, Geza
    Salimi, Hamid
    Duncan, Renee C.
    Moore, Miranda S.
    Ellet, Anne
    Gray, Lachlan R.
    Jubb, Becky
    Westby, Mike
    Purcell, Damian F. J.
    Lewin, Sharon R.
    Lee, Benhur
    Payne, Richard J.
    Churchill, Melissa J.
    Gorry, Paul R.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2014, 30 : A212 - A212
  • [50] In vivo emergence of HIV-1 resistance to the CCR5 antagonist vicriviroc:: findings from ACTG A5211
    Tsibris, A. M. N.
    Gulick, R. M.
    Su, Z.
    Hughes, M. D.
    Flexner, C.
    Wilkin, T.
    Gross, R.
    Hirsch, M.
    Skolnick, P. R.
    Coakley, E.
    Greaves, W. L.
    Kuritzkes, D. R.
    ANTIVIRAL THERAPY, 2007, 12 : S15 - S15
12345